IT-101: Completed Phase I enrollment

Calando completed enrollment in an open-label, dose-escalation, U.S. Phase I trial. Arrowhead Research Corp. (NASDAQ:ARWR, Pasadena, Calif.) is merging its Calando Pharmaceuticals Inc. and Insert Th...